but GSK is not gonna buy now and it makes no sense to buy now..lovaza is generating 250m/quarter..that's a lot of money..they are not gonna give up that easily..they'll see the results of the vascepa penetration and at the same time, they'll wait until they loose atleast 65% of their market before making a move..
GSK in particular is waiting for amarin to fail..i think they'll be the last one's who might make a move to buy amarin..i believe AZN has a good chance to buy amarin as they are loosing their patents by the middle of next year..
I am betting on 27 dollar BO by the end of May..may be more or couple of dollars less than that..
end of may? it will take much longer than that to see how vascepa is penetrating the market and we dont even have anchor yet, not until end of 2013. I do think all the big pharmas are waiting to see how vascepa does in the marketplace, should their be a quick uptake maybe your May day will happen, i think it will be a slow and steady climb with a bo in 2014 with everything in place...yeah they could pay more but its all turn key then...should have anchor fda approval and a decision on nce, scrips number coming in, more patents, suppliers fda approved, just walk in and take it over......imo.......